127 related articles for article (PubMed ID: 21344473)
1. An approach to meta-analysis of dose-finding studies.
Zohar S; Katsahian S; O'Quigley J
Stat Med; 2011 Jul; 30(17):2109-16. PubMed ID: 21344473
[TBL] [Abstract][Full Text] [Related]
2. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
He W; Liu J; Binkowitz B; Quan H
Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
[TBL] [Abstract][Full Text] [Related]
3. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
4. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
5. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Strumberg D; Awada A; Hirte H; Clark JW; Seeber S; Piccart P; Hofstra E; Voliotis D; Christensen O; Brueckner A; Schwartz B
Eur J Cancer; 2006 Mar; 42(4):548-56. PubMed ID: 16426838
[TBL] [Abstract][Full Text] [Related]
6. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of sequential dose-finding designs.
O'Quigley J
Biometrics; 2005 Sep; 61(3):749-56. PubMed ID: 16135026
[TBL] [Abstract][Full Text] [Related]
8. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
Ivanova A; Wang K
Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
[TBL] [Abstract][Full Text] [Related]
9. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
10. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
12. Small-sample behavior of novel phase I cancer trial designs.
Oron AP; Hoff PD
Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
[TBL] [Abstract][Full Text] [Related]
13. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
14. New adaptive method for phase I trials in oncology.
Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
[TBL] [Abstract][Full Text] [Related]
15. A two-stage dose selection strategy in phase I trials with wide dose ranges.
Wang O; Faries DE
J Biopharm Stat; 2000 Aug; 10(3):319-33. PubMed ID: 10959914
[TBL] [Abstract][Full Text] [Related]
16. An optimization algorithm for designing phase I cancer clinical trials.
Jiang H; Liu Y; Su Z
Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
[TBL] [Abstract][Full Text] [Related]
17. An adaptive model switching approach for phase I dose-finding trials.
Daimon T; Zohar S
Pharm Stat; 2013; 12(4):225-32. PubMed ID: 23801550
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
Seegers V; Chevret S; Resche-Rigon M
Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
[TBL] [Abstract][Full Text] [Related]
19. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalation designs in oncology: ADEPT and the CRM.
Shu J; O'Quigley J
Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
